Efficacy of cetuximab for preventing progression of CRC liver metastases after selective portal embolisation.

Trial Profile

Efficacy of cetuximab for preventing progression of CRC liver metastases after selective portal embolisation.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2011

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top